Commerzbank Aktiengesellschaft’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-10,000
Closed -$328K 859
2019
Q2
$328K Buy
+10,000
New +$2.31M ﹤0.01% 834
2019
Q1
Sell
-17,300
Closed -$471K 878
2018
Q4
$471K Hold
17,300
﹤0.01% 674
2018
Q3
$197K Buy
+17,300
New +$5.96M ﹤0.01% 884
2018
Q1
Sell
-30,000
Closed -$11K 949
2017
Q4
$11K Buy
+30,000
New +$9.62M ﹤0.01% 919
2013
Q3
Sell
-55,000
Closed -$11.8M 1305
2013
Q2
$11.8M Buy
+55,000
New +$11.8M 0.05% 279

Other funds holding BIIB

Commerzbank Aktiengesellschaft's BIIB Position: Q2 2020 in Review

Commerzbank Aktiengesellschaft sold out of Biogen (BIIB) in Q2 2020, closing a stake of 4,670 shares — an estimated $1.48M sold.

Commerzbank Aktiengesellschaft first reported a position in BIIB in Q2 2013 and held it in 28 quarters. The position peaked at $80.3M in Q2 2015. 1,059 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

  • Commerzbank Aktiengesellschaft reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 4,670 Biogen shares in Q2 2020, an estimated $1.48M.
  • Commerzbank Aktiengesellschaft first reported a position in Biogen in Q2 2013 and held it in 28 quarters.
  • Commerzbank Aktiengesellschaft's Biogen position peaked at $80.3M in Q2 2015.
  • 1,059 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q2 2020, filed 21 Jul 2020.